Temporal Dynamics of MOG-IgG Status Forty-two of 116 patients (monophasic n = 26, relapsing n = 16) had available serial follow-up testing in both years 1 (months 6–12) and 2 (months 18–24) after onset and were therefore included in our analysis assessing MOG-IgG titer dynamics overtime. MOG-IgG titers did show a statistically significant decrease during the first and second years in monophasic patients, in contrast to a lower decline during the first and second years in relapsing patients.